Editas Medicine (EDIT) Current Assets (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Current Assets of $163.9 million for Q4 2025, down 43.35% year-over-year from $289.3 million in Q4 2024, and down 7.35% quarter-over-quarter from $176.9 million in Q3 2025.
Editas Medicine (EDIT) Current Assets (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Current Assets for 11 consecutive years, with $163.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Assets fell 43.35% year-over-year to $163.9 million; the TTM figure through Dec 2025 stood at $163.9 million (down 43.35% YoY), while the FY2025 annual figure was $163.9 million, down 43.35% from the prior year.
- Current Assets declined to $163.9 million in Q4 2025 per EDIT's latest filing, from $176.9 million in the prior quarter.
- Across five years, Current Assets topped out at $632.3 million in Q1 2021 and bottomed at $163.9 million in Q4 2025.
- Historically, Current Assets has averaged $371.5 million across 5 years, with a median of $348.8 million in 2022.
- Annual changes were most pronounced in 2021 — Current Assets jumped 48.74% — and 2025, when it plunged 43.35%.
- Editas Medicine's Current Assets stood at $507.3 million in 2021, then slipped by 29.68% to $356.8 million in 2022, then decreased by 4.46% to $340.8 million in 2023, then declined by 15.11% to $289.3 million in 2024, then slumped by 43.35% to $163.9 million in 2025.
- Business Quant data shows EDIT's Current Assets at $163.9 million in Q4 2025, $176.9 million in Q3 2025, and $182.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | 163.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 163.90 Mn |
| Sep 30, 2025 | 176.89 Mn |
| Jun 30, 2025 | 182.80 Mn |
| Mar 31, 2025 | 224.84 Mn |
| Dec 31, 2024 | 289.32 Mn |
| Sep 30, 2024 | 271.14 Mn |
| Jun 30, 2024 | 286.35 Mn |
| Mar 31, 2024 | 305.56 Mn |
| Dec 31, 2023 | 340.83 Mn |
| Sep 30, 2023 | 358.60 Mn |
| Jun 30, 2023 | 440.98 Mn |
| Mar 31, 2023 | 324.46 Mn |
| Dec 31, 2022 | 356.75 Mn |
| Sep 30, 2022 | 426.63 Mn |
| Jun 30, 2022 | 461.38 Mn |
| Mar 31, 2022 | 497.03 Mn |
| Dec 31, 2021 | 507.31 Mn |
| Sep 30, 2021 | 567.61 Mn |
| Jun 30, 2021 | 616.29 Mn |
| Mar 31, 2021 | 632.32 Mn |